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Abstract
On March 19, 2008 a Symposium on Pathophysiology of Ageing and Age-Related diseases was held
in Palermo, Italy. Here, the lecture of V. Nicita-Mauro on Smoking, health and ageing is summarized.
Smoking represents an important ageing accelerator, both directly by triggering an inflammatory
responses, and indirectly by favoring the occurrence of several diseases where smoking is a
recognized risk factor. Hence, non-smokers can delay the appearance of diseases and of ageing
process, so attaining longevity.
Background
On March 19, 2008 a Symposium on Pathophysiology of
Ageing and Age-Related diseases was held in Palermo,
Italy. Here, the lecture of V. Nicita-Mauro on Smoking,
health and ageing is summarized.
Ageing is a very complex biological phenomenon deriving
from an interaction between genetic and environmental
factors [1]. Among these latter, the smoke of cigarettes
represents an important accelerator of the ageing process
(Figure 1), both directly through complex mechanisms
mediated prevalently by excessive formation of free radi-
cals, and indirectly by favouring the appearance of various
pathologies in which smoke is a recognized risk factor [2].
Oxidative stress is a possible mechanism consistent with
dangerous effects of smoking since cigarette smoke con-
tains free radicals that activate inflammatory cells with
inflammatory mediator production and further oxidative
damage [3,4]. Smokers have significantly lower erythro-
cyte CuZn SOD and Se-GSH-Px activities than non-smok-
ers [5]. Accordingly, concentrations of serum antioxidant
vitamins, such as ascorbic acid and vitamin E, have been
reported to be lower in chronic smokers than in non-
smokers [6]. Hence, these findings support the concept
that smoking is associated with an increased oxidative
stress that may cause and/or accelerate age-related inflam-
matory diseases [7].
Telomere length represents another possible connection
between smoking and ageing. Telomere length shortens
with age in all replicating somatic cells, and it has been
shown that tobacco smoking enhances telomere shorten-
ing in circulating lymphocytes [8], hence worsening the
immunosenescence state characteristics of ageing [9].
There is no doubt that smoke is an important risk factor
for many diseases, in particular for cardiovascular, neo-
plastic and respiratory diseases, which are the main causes
of death in the industrialized Countries, where smoking
habit is also largely diffuse. According to the projections,
by the year 2020, smoking will become the main cause of
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death and disability, with more than 10 million death
cases per year [2].
Smoking and age-related diseases
Smoking plays an important role also in the development
of other pathological conditions being particularly fre-
quent in old age, such as dementia, osteoporosis, diabe-
tes, peptic ulcer, gastro-esophageal reflux, erectile
dysfunction, senile macular degeneration, nuclear cata-
ract, alterations of hearing and skin. Smoke compromises
not only life expectancy, but also the quality of the life,
favouring the occurrence of non-autonomy (Figure 2) [2].
The role of smoking in dementia and Alzheimer's disease
(AD) has been debated. In the last years, several case-con-
trol studies suggested that smoking was associated with
decreased risk of dementia [7,10]. On the other hand, it
has been hypothesized that findings obtained in case-con-
trol studies were a consequence of survival bias rather
than a true protective effect of smoking [11]. However, the
mechanisms by which smoking would prevent the risk of
AD should be related to the positive nicotinic effects of
smoking on cognitive functioning [7,12]. On the other
hand, the increased frequency of cardiovascular and cere-
brovascular illnesses among smokers is likely to increase
the risk of AD in later life [13,14]. Thus, the association
between smoking and risk of dementia, including AD, is
debated. However, the results of a recent meta-analysis of
prospective studies clearly showed that, when compared
General outline of ageing Figure 1
General outline of ageing. Smoking represents an important exogenous accelerator of ageing process.
Cigarette smoking is an important risk factor for many dis- eases and an accelerator of ageing, it compromises not only  life expectancy but also the quality of life. Figure 2
Cigarette smoking is an important risk factor for 
many diseases and an accelerator of ageing, it com-
promises not only life expectancy but also the quality 
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with people who have never smoked, current smokers
have an increased risk of dementia and cognitive decline
ranging from 40 percent to 80 percent, depending on the
outcome examined [10].
As regards the relationships between smoking and cardio-
vascular system, several studies have shown that smokers
have higher average systolic blood pressure values, com-
pared to non-smokers, further, smokers do not have the
physiological nocturnal decrease of the blood pressure
levels [2]. However, the after-smoking increase of the arte-
rial blood pressure can be abolished by a preventive appli-
cation of the calcium-antagonist nifedipin [15]. The
smoke is able to cause tissue oxidative damage at various
levels, and contributes significantly to the appearance of
endothelial dysfunctions, and to the alterations which
induce the arteriosclerotic process. It is known that in
smoker subjects the oxidative stress derives from excessive
increase of free radicals and reduction of the antioxidant
mechanisms (enzymatic and non-enzymatic type). It has
been shown that the alteration of endothelial vasoregula-
tory activity is independent from the number of smoked
cigarettes, as this activity was similar in subjects who
smoked one package of cigarettes per week or per day (or
less) [2].
A lot of epidemiologic study support the role of smoke in
acute coronary syndrome (ACS) and myocardial infarc-
tion (MI). It is noteworthy that the MI incidence of in Brit-
ain has fallen markedly in recent years. The British
Regional Heart Study examined changes in cardiovascular
risk factors and MI incidence over 25 years from 1978 in
a cohort of 7735 men. The hazard of MI decreased of a
62% decline over the 25 years. Forty-six percent of this
decrease in MI hazard could be explained by a combina-
tion of changes in the major risk factors over this time: a
fall in the number of cigarette smokers was the most pow-
erful of all [16]. Furthermore, in a follow up of 54 783
women and men from the prospective Danish Diet, Can-
cer and Health study who were 50 to 64 years at baseline
and free of coronary artery disease, during a median of 7.7
years, 1127 incident cases of occurred. Obesity conferred
an elevated risk of ACS in both healthy and less healthy
subgroups of lifestyle behaviors: however, the authors
found that obese individuals had a considerable lower
risk if they were nonsmokers [17].
Non-smokers have a much higher life expectancy than
smokers[18], and the suspension of smoking is accompa-
nied, even in the elderly, by an increase in the survival
time due to the reduction of smoke-induced biological
damage. Therefore, cigarette smoking is opposing the lon-
gevity, particularly the extreme one, as it is confirmed by
the observations obtained on centenarians [2]. Tobacco
smoking is associated with a compromised health status
and impaired autonomy also in the centenarians.
Modifiable healthy behaviours during early elderly years,
including smoking abstinence, weight management,
blood pressure control, and regular exercise, are associ-
ated not only with enhanced life span in men but also
with good health and function during old age [19].
Considering the demonstrated beneficial effects of sus-
pension of smoking, all practitioners and geriatricians in
particular, should promote the abstinence from smoking
as a behavioural norm for a correct life style.
Therefore, it is our duty to notify non smokers to keep
non-smoking, and to the smokers to abandon smoking,
evidencing the risks related to smoking, and the limita-
tions to health deriving from this habit. On the other
hand, we have to illustrate also the better performance
that non-smokers may achieve. The invitation by the prac-
titioner to stop smoking may be effective, but often this
possibility is not utilized properly, in particular as far as
elderly subjects is concerned: indeed these subjects often
were never been told to leave smoking [20].
Conclusions: Stopping Smoking
The first requirement of stopping smoking is certainly the
motivation of the smoker himself to do this, since without
this motivation any attempt is vane. Today, numerous
strategies exist, either of pharmacological or non-pharma-
cological type, which are advantageous also for the eld-
erly. The most effective smoking cessation programs
involve a combination of pharmacotherapy and behav-
ioural and/or cognitive counselling to improve abstinence
rates.
Approved pharmacological treatments include nicotine
replacement therapies, bupropion, a non nicotine option,
antidepressants, drugs targeting cannabinoid receptors
and newer pharmacological approaches including the
selective nicotinic partial agonists [21-26].
Nicotine can be applied in various ways, but the best is
certainly the transdermic method through the application
of patches. The efficacy of the nicotine patches has widely
been documented in a series of studies, together with the
contraindications, the side effects, the pharmacological
interactions, even for the elderly subjects [20,21]. Another
method is the use of an antidepressant, called bupropi-
one, which has demonstrated good efficacy as both a
monotherapy, and in association with nicotine patches
[22].
Varenicline, an alpha4beta2 nicotinic acetylcholine recep-
tor partial agonist, is the most recent agent approved forPublish with BioMed Central    and   every 
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smoking cessation. This drug works by reducing the
strength of the smoker's urge to smoke and by relieving
withdrawal symptoms. Varenicline mimics the effect of
nicotine and hence reduces craving when smokers stop.
Furthermore, varenicline blocks nicotine receptors and in
this manner, provokes a weaker response to nicotine if
smokers use tobacco products while taking the drug.
Recent evidence suggests that the nicotin-receptor partial
agonist varenicline is at least as effective as nicotine
replacement therapy and antidepressants [23-26].
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